Key Takeaways:
- Regeneron is executing a comprehensive strategy focused on pipeline diversification while expanding commercial reach across its blockbuster drug portfolio.
- REGN stock could reasonably reach $784/share by the end of 2027, based on our valuation assumptions.
- This implies a total return of 33% from today’s price of $591/share, with an annualized return of 13% over the next 2.4 years.
Regeneron (REGN) is establishing new benchmarks in the global biotechnology industry through a strategic focus on innovative drug development.
The company continues to expand monetization across its diverse therapeutic portfolio spanning ophthalmology, immunology, oncology, and hematology.
Regeneron combines its core research expertise with approximately 45 product candidates in clinical development. This approach captures evolving patient needs across multiple disease areas, from rare genetic disorders to prevalent inflammatory conditions affecting millions worldwide.
The biotechnology leader serves patients globally through its comprehensive therapeutic ecosystem. Key franchises include EYLEA for retinal diseases, Dupixent for type 2 inflammatory conditions, and emerging programs in cancer bispecifics.
This spans from established blockbuster franchises through innovative pipeline candidates like Lynozyfic and odronextamab that address significant unmet medical needs.
REGN stock benefits from strong momentum, delivering $3.7 billion in Q2 revenue, representing 4% year-over-year growth and achieving robust diluted earnings per share of $12.89, up 12% from the prior year, with exceptional free cash flow generation of $1.7 billion in the first half of 2025.
Regeneron demonstrates clear execution across all segments with Dupixent global sales of $4.3 billion growing 21% on a constant currency basis, EYLEA HD U.S. sales reaching $393 million, representing 29% growth, and Libtayo global sales expanding 25% while establishing market leadership positions.
Regeneron’s strategic transformation under CEO Leonard Schleifer focuses on delivering breakthrough medicines that provide long-term patient value while building sustainable competitive advantages through proprietary R&D capabilities and strategic capital allocation for its increasingly global patient base.
With initiatives including FDA approval of Lynozyfic as the first hematology product with a differentiated profile, strong Dupixent expansion across eight approved indications, and robust pipeline advancement in thrombosis and obesity markets, Regeneron continues building comprehensive therapeutic leadership.
With Q2 results showing sustained profitability and innovation success while maintaining significant R&D investment of approximately $5 billion annually, REGN stock is positioned for continued expansion as the pipeline diversification strategy drives long-term value creation across multiple therapeutic areas.
Here’s why REGN stock could deliver solid returns through 2027 as it captures diverse therapeutic opportunities while scaling breakthrough innovations across its expanding pipeline.
See analysts’ full growth forecasts and estimates for Regeneron (It’s free) >>>
What the Model Says for REGN Stock
We analyzed the upside potential for REGN stock using valuation assumptions based on its innovation capabilities and expanding therapeutic market opportunities across multiple disease areas.
Analysts see significant opportunity ahead for Regeneron stock given its proven drug development track record, robust pipeline with 45 candidates, and systematic approach to building sustainable competitive advantages while maintaining industry-leading R&D productivity and commercial execution.
Regeneron’s diversified therapeutic strategy provides multiple growth vectors while its innovation focus validates that strong execution can drive market differentiation and patient outcome improvements in the competitive biotechnology landscape.
Based on estimates of 4.0% annual revenue growth, 34% operating margins, and a normalized P/E valuation multiple of 16.0x, the model projects REGN stock could rise from $591/share to $784/share.
That would be a 33% total return, or a 13% annualized return over the next 2.4 years.
Value Regeneron with TIKR’s Valuation Model today for FREE (Find undervalued stocks fast) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for REGN stock:
1. Revenue Growth: 4%
Regeneron delivered a solid Q2 performance with revenue growing 4% year-over-year despite EYLEA headwinds, while achieving strong growth across key franchises, including Dupixent’s 21% constant currency expansion and the successful launch of new therapeutic programs.
REGN expects momentum from pipeline diversification with anticipated Phase III data across multiple programs, continued Dupixent expansion into new indications and patient populations, and emerging opportunities in obesity, thrombosis, and genetic medicines while navigating established product competitive dynamics.
We used a 4.0% forecast reflecting Regeneron’s proven ability to develop breakthrough therapies and navigate competitive markets while building sustainable pipeline value across diverse therapeutic areas.
2. Operating Margins: 34%
Regeneron achieved strong operational performance with robust margins supported by blockbuster drug profitability and disciplined expense management, demonstrating a successful balance between significant R&D investment and commercial excellence.
Focus on operational efficiency through established product franchises and pipeline advancement, which supports margin maintenance while funding extensive R&D programs, manufacturing expansion, including a $7 billion U.S. investment, and strategic business development initiatives.
Management targets sustainable long-term margin performance while investing heavily in innovation, reflecting disciplined capital allocation balancing profitability with market leadership and competitive positioning across multiple therapeutic areas.
3. Exit P/E Multiple: 16x
REGN stock trades at reasonable multiples reflecting the company’s innovation leadership and expanding addressable market opportunities across diverse therapeutic areas.
We maintain conservative valuation levels given Regeneron’s proven drug development capabilities, strong commercial execution track record, and systematic approach to building sustainable competitive advantages through proprietary research platforms and strategic partnerships.
Long-term competitive advantages from innovation leadership, diverse therapeutic portfolio, and operational excellence should support reasonable valuations as execution demonstrates sustained pipeline advancement and commercial success across multiple disease areas.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for Regeneron stock through 2030 show varied outcomes based on execution and biotechnology market expansion success: (these are estimates, not guaranteed returns):
- Low Case: Slower pipeline advancement and competitive pressures → 6% annual returns
- Mid Case: Successful pipeline execution and continued innovation → 11% annual returns
- High Case: Strong breakthrough approvals and market leadership → 16% annual returns
Even in the conservative case, REGN stock offers attractive returns supported by its unique innovation positioning and proven ability to develop breakthrough therapies across diverse therapeutic areas with significant unmet medical needs.
The upside scenario for REGN stock could deliver exceptional performance if Regeneron successfully captures expanded pipeline opportunities and maintains market leadership through continued innovation and commercial execution across its comprehensive biotechnology platform.
See analysts’ growth forecasts and price targets for any stock (It’s free!) >>>
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
